GlassScriptPhysician profile
Boris D Ratiner
NPI 1821001496
$34,979.54
in general payments reported to CMS, 2019-2025
49 companies · $4,686 in 2025
The $4,686 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,873 · 2020: $3,823 · 2021: $3,905 · 2022: $5,135 · 2023: $9,420 · 2024: $5,137 · 2025: $4,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $4,985 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,100.21 |
| Consulting Fee | $4,985.00 |
| Education | $157.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,925.50 | 2019-2025 | Ofev, Cyltezo |
| Abbvie INC. | $5,914.62 | 2019-2025 | |
| Amgen INC. | $4,600.56 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $3,578.96 | 2019-2025 | Tremfya, Remicade, Stelara |
| Novartis Pharmaceuticals Corporation | $3,058.18 | 2019-2025 | |
| Ucb, INC. | $1,478.76 | 2020-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,249.43 | 2020-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,152.22 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $863.96 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $721.75 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $592.57 | 2021-2025 | Saphnelo |
| Pfizer INC. | $565.23 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $543.25 | 2019-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $338.80 | 2019-2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $281.38 | 2022-2025 | Purified Cortrophin Gel |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $276.06 | 2021-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Enterprises LLC | $254.92 | 2019 | |
| Hikma Pharmaceuticals USA | $241.88 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $230.67 | 2020-2025 | Acthar |
| Celgene Corporation | $212.75 | 2019 | |
| Aurinia Pharma U.S., INC. | $182.11 | 2022-2025 | Lupkynis |
| Organon LLC | $174.54 | 2023-2025 | Nexplanon, Hadlima |
| Fresenius Kabi USA, LLC | $157.48 | 2023-2025 | Idacio |
| Genzyme Corporation | $137.98 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $115.45 | 2023-2025 | |
| Spr Therapeutics, INC | $102.52 | 2024 | Sprint Pns System |
| Angiodynamics, INC. | $100.77 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $95.22 | 2024 | Arcalyst |
| Depuy Synthes Sales INC. | $93.53 | 2021-2024 | Monovisc, Orthovisc |
| Sobi, INC | $78.18 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $75.05 | 2019-2021 | |
| Celltrion USA INC. | $74.48 | 2025 | Vegzelma |
| Sanofi-Aventis U.S. LLC | $64.99 | 2023 | |
| Gilead Sciences, INC. | $51.52 | 2019-2020 | |
| Medexus Pharma, INC. | $47.55 | 2019 | |
| Lundbeck LLC | $43.30 | 2022-2024 | Vyepti |
| Vertiflex, INC. | $41.78 | 2019 | |
| Kyowa Kirin, INC. | $37.05 | 2023 | Crysvita |
| Bioventus LLC | $36.55 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $31.11 | 2024 | Zilretta |
| Novo Nordisk INC | $26.22 | 2025 | Wegovy, Saxenda |
| Scilex Pharmaceuticals INC. | $22.48 | 2024 | |
| Fidia Pharma USA INC. | $22.24 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.52 | 2019 | |
| Eisai INC. | $18.51 | 2023 | |
| Genentech USA, INC. | $18.33 | 2024 | Actemra |
| Alvogen INC | $16.41 | 2025 | Teriparatide |
| Tactile Systems Technology INC | $13.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$89,998.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Ratiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.